Rodríguez-García A, Gómez VJA, Martínez-Calva IE

Language: Spanish
References: 11
Page: 521-525
PDF size: 192.14 Kb.

ABSTRACT

Background: Chronic kidney disease is a condition characterized by deterioration of the glomerular filtration rate coupled with inherent gastrointestinal, hematological, cardiovascular and mineral bone symptoms that condition a decrease in the quality of life of a patient. According to statistics from the United States, in 2012, Mexico, represented by the state of Jalisco, had the first place on incidence per million inhabitants and the sixth place on prevalence, below countries like Taiwan, Japan and the United States. Objective: To compare the dry weight of patients with chronic renal failure in the treatment of function by peritoneal dialysis using icodextrin with those using standard glucose solutions. Material and methods: Retrospective and observational study performed in the clinical archive service, the nephrology ward and the external dialysis consultation of the Central Military Hospital from April to September 2015. The parameters to be evaluated were dry weight, hemoglobin and albumin. The analysis was carried out using the statistical paired t method. Results: In relation to dry weight, a statistically significant difference was obtained, with a value of p ‹ 0.05, showing that icodextrin keeps patients closer to dry weight than standard glucose solutions, translated on an average of 3.3 versus 4.2 L, icodextrin versus conventional, respectively. Conclusions: The use of icodextrin in patients with peritoneal dialysis helps to preserve the peritoneal cavity and improve the metabolic, volumetric and blood pressure control without affecting residual diuresis.

REFERENCES

1. Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J et al. US renal data system 2014 annual data report: epidemiology of kidney disease in the united states. Am J Kidney Dis. 2015; 66 (1 Suppl 1): Svii, S1-S305.

2. Celik G, Kara I, Yilmaz M, Apiliogullari S. The relationship between bioimpedance analysis, haemodynamic parameters of haemodialysis, biochemical parameters and dry weight. J Int Med Res. 2011; 39 (6): 2421-2428.

3. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol. 2012; 23 (6): 1097-1107.

4. Silver SA, Harel Z, Perl J. Practical considerations when prescribing icodextrin: a narrative review. Am J Nephrol. 2014; 39 (6): 515-527.

5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39 (2 Suppl 1): S1-266.

6. Ávila-Saldivar MN. Enfermedad renal crónica: prevención y detección temprana en el primer nivel de atención. Med Int Mex. 2013; 29 (2): 148-153.

7. Méndez-Durán A, Méndez-Bueno JF, Tapia-Yáñez T, Muñoz Montes A, Aguilar-Sánchez L. Epidemiología de la insuficiencia renal crónica en México. Dial Traspl. 2010; 31 (1): 7-11.

8. Andrassy KM. Comments on ‘KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease’. Kidney Int. 2013; 84 (3): 622-623.

9. Guías S.E.N. Tratamiento sustitutivo de la insuficiencia renal crónica. NAC 1999.

10. Qiang He, Wei Zhang and Jianghua Chen, A Meta-Analysis of Icodextrin versus Glucose Containing Peritoneal Dialysis in Metabolic Management of Peritoneal Dialysis Patients, Renal Failure, 2011; 33 (10): 943–948.

11. Liu Li, Long Gang, A randomized controlled trial of long term effect of BCM guided fluid management in MHD patients (BOCOMO study): rationales and study design, BMC Nephrology 2012, 13: 120.